$54.19
0[0.00%]
At close: Apr 25
$54.19
0[0.00%]
PreMarket: 4:20PM EDT
Keros Therapeutics
(NASDAQ:KROS)Keros Therapeutics Stock (NASDAQ:KROS), Analyst Ratings, Price Targets, Predictions
Keros Therapeutics Inc has a consensus price target of $77.63, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Truist Securities, and HC Wainwright & Co. on March 27, 2024, March 13, 2024, and March 1, 2024. With an average price target of $101.67 between Piper Sandler, Truist Securities, and HC Wainwright & Co., there's an implied 87.61% upside for Keros Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Truist Securities
HC Wainwright & Co.
Wells Fargo
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Keros Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | KROS | Buy Now | Keros Therapeutics | $54.19 | 93.76% | Piper Sandler | Joseph Catanzaro | → $105 | Maintains | Overweight | Get Alert |
| 03/13/2024 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | Truist Securities | Srikripa Devarakonda | → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 10.72% | Wells Fargo | Tiago Fauth | → $60 | Initiates | → Overweight | Get Alert |
| 11/13/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 58.7% | Wedbush | Andreas Argyrides | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 58.7% | Wedbush | Andreas Argyrides | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 58.7% | Wedbush | Andreas Argyrides | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 58.7% | Wedbush | Andreas Argyrides | → $86 | Initiates | → Outperform | Get Alert |
| 07/26/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 19.95% | B of A Securities | Greg Harrison | → $65 | Initiates | → Buy | Get Alert |
| 06/09/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | → Buy | Get Alert |
| 05/08/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 102.99% | Piper Sandler | Joseph Catanzaro | $120 → $110 | Maintains | Overweight | Get Alert |
| 03/06/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | HC Wainwright & Co. | Andrew Fein | → $100 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | KROS | Buy Now | Keros Therapeutics | $54.19 | — | Cowen & Co. | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 12/13/2022 | KROS | Buy Now | Keros Therapeutics | $54.19 | 93.76% | BTIG | Julian Harrison | $95 → $105 | Maintains | Buy | Get Alert |
| 10/18/2022 | KROS | Buy Now | Keros Therapeutics | $54.19 | 84.54% | Truist Securities | Srikripa Devarakonda | → $100 | Initiates | → Buy | Get Alert |
| 07/26/2022 | KROS | Buy Now | Keros Therapeutics | $54.19 | 47.63% | BTIG | Julian Harrison | → $80 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Keros Therapeutics (KROS)?
The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Piper Sandler on March 27, 2024. The analyst firm set a price target for $105.00 expecting KROS to rise to within 12 months (a possible 93.76% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Keros Therapeutics (KROS)?
The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Piper Sandler, and Keros Therapeutics maintained their overweight rating.
When was the last upgrade for Keros Therapeutics (KROS)?
There is no last upgrade for Keros Therapeutics.
When was the last downgrade for Keros Therapeutics (KROS)?
There is no last downgrade for Keros Therapeutics.
When is the next analyst rating going to be posted or updated for Keros Therapeutics (KROS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating Keros Therapeutics (KROS) correct?
While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a maintained with a price target of $0.00 to $105.00. The current price Keros Therapeutics (KROS) is trading at is $54.19, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.